SciSparc Subsidiary Granted US Patent for Cannabinoid-Enhanced Antimicrobial Technology

summarizeSummary

SciSparc's majority-owned subsidiary, NeuroThera Labs, secured a U.S. patent for its cannabinoid-enhanced technology designed to combat antimicrobial resistance, including MRSA.

check_boxKey Events

• U.S. Patent Granted

  NeuroThera Labs Inc., a SciSparc majority-owned subsidiary, received a U.S. patent for its proprietary cannabinoid-enhanced antimicrobial technology.

• Combats Antimicrobial Resistance

  The patented technology combines existing antimicrobials with cannabinoids (THC, CBD, PEA) to enhance efficacy against resistant Gram-positive pathogens, such as MRSA.

• Strengthens IP Portfolio

  This U.S. patent adds to previously granted patents for the same technology in the U.S. and Europe, bolstering global intellectual property protection.

• Addresses Global Health Threat

  The technology targets antimicrobial resistance, a growing crisis with MRSA alone causing approximately 130,000 deaths worldwide in 2021.

auto_awesomeAnalysis

This patent grant significantly strengthens SciSparc's intellectual property portfolio through its controlling interest in NeuroThera Labs. The patented technology, which combines existing antibiotics with cannabinoids, aims to restore efficacy against resistant bacterial strains like MRSA, a critical global health threat. While the technology is currently in pre-clinical stages, this patent provides a crucial foundation for future development in a large and underserved market, potentially offering a novel solution to the escalating challenge of antibiotic resistance. This positive development follows a period of significant financing and acquisition activity for the company.